NCT07840950Not yet recruiting

Effects of Rosa Roxburghii Tratt Freeze-Dried Powder on Carotid Atherosclerotic Plaques: A Real-World Study

Mechanism of Action and Real-World Study of Rosa Roxburghii Tratt Freeze-Dried Juice Powder and Its Extracts Against Carotid Atherosclerotic Plaques

Source: ClinicalTrials.gov · Last updated 25 Sept 2026

Brief summary (registry, in English)

This study aims to evaluate the effectiveness and safety of Rosa roxburghii freeze-dried powder in reducing carotid atherosclerotic plaques. Carotid atherosclerosis is a major cause of ischemic stroke, and current treatments have safety limitations. Rosa roxburghii, a fruit used in traditional Chinese medicine, has shown potential in lowering lipids and reducing inflammation. In this randomized controlled trial, 200 participants with carotid plaques will be assigned to either conventional therapy alone or conventional therapy plus Rosa roxburghii freeze-dried powder (3 g/day for 6 months). The primary outcomes are changes in plaque size assessed by ultrasound and serum lipid levels. Secondary and exploratory outcomes include changes in inflammatory markers, gut microbiota composition, and metabolomic profiles. The study will provide clinical evidence on the use of Rosa roxburghii as an adjunctive therapy for atherosclerosis.

Status (registry): Not yet recruiting
Study type: Interventional
Enrollment: 200 (estimated)
First submitted: 14 Sept 2026
Start date: 1 Sept 2026
Primary completion date: 31 Dec 2028
Lead sponsor: Xiangya Hospital of Central South University
Diseases: Stroke
NCT number: NCT07840950

What you commit to

Study type: Interventional
Planned participants: 200
From 1 Sept 2026 to the primary completion date, 31 Dec 2028
No sites listed in no country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Concomitant liver or kidney disease
Use of antibiotics, probiotics, prebiotics, laxatives, or traditional Chinese medicine within 3 months prior to enrollment

Other illness

History of allergy to Rosa roxburghii juice or vitamin C preparations
Psychiatric disorders or inability to cooperate with the study procedures
Diagnosis of diabetes mellitus or hypertension
Any condition that, in the investigator's opinion, makes the participant unsuitable for enrollment

Other

Hyperlipidemia without detectable carotid plaques
Severe malnutrition
Pregnancy or lactation

Who the study is looking for

Participants clinically diagnosed with atherosclerosis (AS) by a specialist physician
Age between 40 and 80 years
Presence of at least one identifiable carotid plaque meeting all of the following criteria: (a) a focal structure protruding into the lumen; (b) on gray-scale ultrasound longitudinal/transverse sections, protrusion beyond the vascular intimal surface with a maximum thickness ≥ 1.5 mm compared with the adjacent normal vessel wall (1-2 cm proximal or distal to the plaque); (c) a local structure protruding into the lumen with a thickness ≥ 0.5 mm or \> 50% of the surrounding intima-media thickness (IMT), accompanied by abnormal lipid metabolism markers
Diagnosis of carotid plaque and regular follow-up with the same physician at the study site
Willingness to refrain from participating in other clinical studies and to complete the full treatment regimen during the study period
Voluntarily sign the informed consent form after being fully informed

Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.